– Vision of Hope Award to be presented at the SFA’s 15th Annual Fundraising Gala –
DAMASCUS, Md. – April 10, 2017– The Sarcoma Foundation of America (SFA), an organization dedicated to increased research funding and advocacy for sarcoma, is pleased to announce that Lilly Oncology is the 2017 recipient of the Vision of Hope Award. Lilly Oncology will be honored at the SFA’s 15th Annual New York fundraising gala, “A Celebration of Life.” The event will take place on April 20, 2017, at Guastavino’s, 409 E 59th Street, New York, NY.
The Vision of Hope Award is presented to a person or organization whose achievements provide increased hope for better patient outcomes. Awardees receiving this honor have contributed in a significant way to the advancement of care, treatment, and hope for sarcoma patients.
The SFA is proud to honor Lilly Oncology with the Vision of Hope Award for their work in developing and bringing to patients Lartruvo™ (olaratumab) the first front-line therapy for soft tissue sarcoma approved by the Food and Drug Administration (FDA) in more than 40 years.
“Lilly has brought to patients an amazing advancement in the treatment of soft tissue sarcoma,” said SFA Chief Executive Officer Bert E. Thomas IV, Ph.D., MBA. “The impact of this new therapy is significant as it provides new hope for better outcomes for patients who have been in great need of new and better therapeutic options. The Sarcoma Foundation of America is proud to acknowledge this achievement and recognize Lilly Oncology for their contribution to improving the sarcoma treatment landscape.”
“Lilly is honored to receive this award from the Sarcoma Foundation of America, an organization that is relentless in its pursuit of advancing research and creating greater awareness of this rare form of cancer,” said Symantha Melemed, Ph.D., global team leader for Lartruvo at Lilly Oncology. “People with sarcoma have unique challenges, from obtaining an accurate and timely diagnosis, to identifying the right doctor and treatment plan. The Sarcoma Foundation of America has a rich history in helping to make life better for people living with sarcoma, and we are proud to stand alongside them.”
“A Celebration of Life” honors those who have battled sarcoma, as well as those who have dedicated their lives and careers to the treatment of sarcoma patients. The event raises money to fund innovative sarcoma research that will lead to the development of new and better therapies for sarcoma patients. Further information about the Sarcoma Foundation of America and the 2017 fundraiser, “A Celebration of Life,” can be found at https://www.curesarcoma.org/nyccelebration/.
About the Sarcoma Foundation of America
The Sarcoma Foundation of America (SFA), a 501(c)(3) nonprofit charitable organization, is an advocate for increased research to find new and better therapies with which to treat patients with sarcoma. The organization raises money to privately fund grants for sarcoma researchers and conducts education and advocacy efforts on behalf of sarcoma patients. For more information, please visit www.curesarcoma.org.
Sarcoma is a rare cancer in adults (1 percent of all adult cancers) but rather prevalent in children (about 20 percent of all childhood cancers). At any one time, 50,000 patients and their families are struggling with sarcoma. Every year, nearly 15,000 new cases are diagnosed and about 6,000 people die from the disease.
About Lilly Oncology
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.
Lilly Oncology has provided funding to the Sarcoma Foundation of America for educational programs.